# Immutep's EFTISARC-NEO Shows 81.1% Disease-Free Survival at 12 Months in Soft Tissue Sarcoma

> Immutep reported 81.1% 12-month disease-free survival in its EFTISARC-NEO Phase II sarcoma trial, with 95.0% DFS in patients with higher TIL levels.

- Published: 2026-11-19T00:54:16+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-19/immutep-eftisarc-neo-disease-free-survival
- Source: [TradingView](https://www.tradingview.com/news/tradingview:85c1a02291d43:0-immutep-limited-imm-reports-81-1-12-month-dfs-in-sarcoma-trial/)

## Key takeaways

- Immutep reported 81.1% disease-free survival at 12 months in the EFTISARC-NEO Phase II trial in resectable soft tissue sarcoma.
- Patients with post-treatment TIL levels above 310 cells/mm² had 95.0% 12-month DFS versus 64.9% for lower levels.
- Eight of 38 evaluated patients had recurrence by April 30, 2026, and a registration-directed trial is planned for H2 2027.

[Immutep](https://akta.pro/company-profiles/0003b9a/immutep) reported 81.1% disease-free survival at 12 months in its EFTISARC-NEO Phase II trial in resectable soft tissue sarcoma, data presented at CTOS 2026. [TradingView](https://www.tradingview.com/news/tradingview:85c1a02291d43:0-immutep-limited-imm-reports-81-1-12-month-dfs-in-sarcoma-trial/) carried the company's announcement on November 19, 2026. The 18-month Kaplan-Meier estimate is also 81.1% but remains immature.

## What the EFTISARC-NEO Poster Showed

The poster presented at CTOS 2026 expands on survival data first reported in an abstract announced on November 11, 2026. Patients with post-treatment tumour-infiltrating lymphocyte levels above 310 cells/mm² had 95.0% 12-month disease-free survival, compared with 64.9% in patients with lower TIL levels. Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month disease-free survival, compared with 71.4% in patients with lower levels. Eight of 38 patients evaluated had recurrence by April 30, 2026. Immutep said the results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy. The company said a registration-directed trial is planned for the second half of 2027.

## Immutep's Sarcoma Program in Company Records

According to akta.pro [company records](https://akta.pro/company-data), the FDA granted Orphan Drug Designation to eftilagimod alfa for soft tissue sarcoma in April 2026, providing seven-year US market exclusivity and supporting the EFTISARC-NEO Phase II program, which had previously met its primary endpoint with 51.5% median tumor hyalinization/fibrosis. The same records show Immutep held A$129 million in cash reserves as of March 2026, expected to extend beyond previous guidance due to trial discontinuation. Immutep is a Sydney-based biotechnology company founded in 2001 that develops LAG-3 related immunotherapies for cancer and autoimmune diseases, according to its profile.

## Earlier Steps Toward the Sarcoma Readout

Immutep said on July 24, 2026 that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial of eftilagimod alfa had been accepted for presentation at the ESMO Congress 2026 in Madrid, scheduled for October 23–27, 2026, [GlobeNewswire](https://www.immutep.com) reported. On September 11, 2026, Stock Titan reported that Immutep will focus future registration-directed development of eftilagimod alfa on head and neck squamous cell carcinoma with CPS <1 and neoadjuvant soft tissue sarcoma. Business & Financial reported on November 5, 2026 that Immutep will present poster data from the EFTISARC-NEO Phase II trial and the TACTI-003 Part B study at CTOS 2026 and ESMO 2026.

## Immutep's Next Data and Trial Steps

Immutep is scheduled to present Phase 1 data on IMP761 at ACR Convergence in Orlando on November 10, 2026, following late-breaking abstract acceptance, The future of trading reported on October 18, 2026. The company has targeted initiation of a registration-directed trial for the second half of 2027.

## Companies in this story

- [Immutep company profile](https://akta.pro/company-profiles/0003b9a/immutep) · website: https://www.immutep.com

---
News for Agent · https://newsforagent.com/llms.txt
